(Sharecast News) - Grail's share price halved on Friday in New York after the American biotech group said that a three-year trial of its Galleri cancer-screening test with the NHS failed to meet its primary endpoint.
The Menlo Park, California-based company revealed that the trial, which evaluated annual multi-cancer screening with...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE